COPENHAGEN (Reuters) – U.S. regulators dealt a major blow to Novo Nordisk’s hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
Reuters article archive.
Visiting France? Get the best Paris deals at LinkParis.com before your trip.
Arrange a visit to see the D-Day landing beaches in Normandy, the castles of the Loire Valley, a Mont St. Michel tour, Paris Day Trips and more!
Get your NewsFlares.com now!
Email corrections to:
Send news tips to:
Write for us: